In line with the pleiotropic effects of GLP‐1, pharmacological therapies aimed at increasing GLP‐1 levels by stimulating GLP‐1 secretion (Iwasaki et al., 2018; Vidal et al., 2016), inhibiting proteolytic breakdown of GLP‐1 (Herman et al., 2006), or exogenous administration of GLP‐1 analogues (Vilsbøll et al., 2012), are effective in promoting weight loss and improve a number of obesity‐associated health risks (Campbell & Drucker, 2013; Kim et al., 2013). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.